Research Grid Raised $6.48M to Drive Automation in Clinical Trials

by BiopharmaTrend       News

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

  
Topics: Clinical Trials   
Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email   |  

Research Grid has secured $6.48 million in seed funding, led by Fuel Ventures, with additional support from Arve Capital, Ada Ventures, and Morgan Stanley Inclusive Ventures Lab, among others. The funding will advance Research Grid’s mission to automate the back-office administration of clinical trials, aiming to streamline processes across patient recruitment, data management, and reporting. Clinical trial delays, largely due to legacy software and manual tasks, currently cost up to $400 million annually per Phase 3 trial.

Research Grid's platform consists of two key products: Inclusive, which optimizes patient recruitment by offering access to 91,000 vetted global communities across 2,050 medical conditions, and TrialEngine, which automates administrative workflows during trials, from protocol setup to data extraction. Powered by proprietary AI algorithms, these products enable customers to see 98% efficiency improvements, 45% cost savings, and a 145% boost in patient engagement.

TrialEngine sysetem, from product's webpage.

Founded by Dr. Amber Hill, a neuroscientist with a background in AI, Research Grid leverages Hill's firsthand experience with the bottlenecks in clinical trials. With additional investment, the company plans to expand its R&D and engineering teams, focusing on U.S. and Asian market growth. This comes at a pivotal time, as the clinical trial market is projected to surpass $95 billion by 2029, with automation seen as a vital driver of efficiency and success.

Topics: Clinical Trials   

Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email